Identification of novel canonical and cryptic HCMV-specific T-cell epitopes for HLA-A*03 and HLA-B*15 via peptide-PRISM

Author:

Rein Alice Felicitas1ORCID,Lauruschkat Chris David1ORCID,Muchsin Ihsan2ORCID,Köchel Carolin1,Tischer-Zimmermann Sabine3,Bauersfeld Liane4,Nelde Annika5ORCID,Lübke Maren6,Prusty Bhupesh Kumar2,Schlosser Andreas7ORCID,Halenius Anne8,Eiz-Vesper Britta9ORCID,Dölken Lars10ORCID,Grigoleit Götz Ulrich11,Einsele Hermann12,Erhard Florian13ORCID,Kraus Sabrina14

Affiliation:

1. University Hospital of Wuerzburg, Würzburg, Germany

2. Julius-Maximilians-University Wuerzburg, Wuerzburg, Würzburg, Germany

3. Hannover Medical School, Hannover, Germany

4. University Hospital of Freiburg, Freiburg, Germany

5. Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Germany

6. Institute for Cell Biology, University of Tübingen, Germany, Tübingen, Germany

7. University of Würzburg, Würzburg, Germany

8. University of Freiburg, Freiburg, Germany

9. Medical School Hannover, Hannover, Germany

10. Julius Maximilians Universität Würzburg, Würzburg, Germany

11. Helios Klinikum Duisburg, Duisburg, Germany

12. Universitätsklinikum Würzburg, Würzburg, Germany

13. Universität Regensburg, Regensburg, Germany

14. Uniklinikum Würzburg, Würzburg, Germany

Abstract

Human cytomegalovirus (HCMV) reactivation poses a substantial risk to transplant patients. Effective risk stratification and vaccine development is hampered by a lack of HCMV-derived immunogenic peptides in patients with common HLA-A*03:01 and HLA-B*15:01 haplotypes. This study aimed to discover novel HCMV immunogenic peptides for these haplotypes by combining Ribo-seq and mass spectrometry with state-of-the-art computational tools, Peptide-PRISM and PRICE. Furthermore, employing machine learning, an algorithm was developed to predict immunogenicity based on translational activity, binding affinity and peptide localization within small open reading frames to identify the most promising peptides for in vitro validation. Immunogenicity of these peptides was subsequently tested by analyzing peptide-specific T-cell responses of HCMV-seropositive and -seronegative healthy donors as well as transplant patients. This resulted in the direct identification of three canonical and one cryptic HLA-A*03-restricted immunogenic peptides as well as five canonical and one cryptic HLA-B*15-restricted immunogenic peptide, with a specific IFNγ+/CD8+ T-cell response of ≥ 0.02%. High T-cell responses were detected against two HLA A*03-restricted and three HLA-B*15-restricted canonical peptides with frequencies of up to 8.77% IFNγ+/CD8+ T cells in patients post alloSCT. Therefore, our comprehensive strategy establishes a framework for efficient identification of novel immunogenic peptides from both existing and novel Ribo-seq datasets.

Publisher

American Society of Hematology

Subject

Hematology

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3